Younity:
ALK+, ROS1+, RET+ NSCLC
CLIENT: F. Hoffmann-La Roche
AGENCY: Havas Lynx Group
​
In this day and age, the causes of lung cancer and the outcomes for patients are not what they used to be—especially for those who have lung cancer driven by rare alterations such as ALK, ROS, and RET.
​
Younity was developed to give these patients an online hub, tailored to their disease and needs.​
Younity website
Lung cancer has always been one of the most common cancers worldwide. But where the typical patient was an older smoker/ex-smoker, we're now seeing a rise in younger patients with no smoking history.
​
Recent research has unearthed cancer driving alterations—like ALK, ROS, and RET—which are sometimes the culprit in these patients. However, when they turn to the internet to find information that applies to them most of it is still written based on the archetypal smoker, leaving them with no tailored information about their specific disease, its causes, or treatment options.
Younity was developed to tackle this very problem. Working in close partnership with ALK/ROS/RET and other rare-alteration cancer patients, we created a site that was tailored to their needs, and their disease.
​
Covering everything from what a mutation is, to symptoms and their management, treatments, and even considerations about palliative care, Younity provided a comprehensive one-stop site to ensure patients were able to easily find answers about their cancer.
Our patient partners told us that they wanted hopeful and uplifting informative content, so medical worked closely with our creative team, to give the site a positive tone of voice, and look and feel. This extended through to videos made with our patient partners, and downloadable content made to support patients with their appointments and scans.
Younity was localised in a number of countries, and recognised internally at Roche as an outstanding example of working with patients to develop meaningful content as part of their portfolio.